| scholarly article | Q13442814 |
| P50 | author | Silvia V Lourenco | Q63696998 |
| Ricardo Hsieh | Q51163435 | ||
| P2093 | author name string | Juliana D Fernandes | |
| Marcello M S Nico | |||
| Martin Sangueza | |||
| Luiz A R de Freitas | |||
| Miguel A R Brandao | |||
| P2860 | cites work | Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. | Q53640355 |
| KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. | Q54411917 | ||
| NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. | Q54570448 | ||
| In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation | Q61640129 | ||
| Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation | Q73013877 | ||
| N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin | Q77519474 | ||
| Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi | Q82281827 | ||
| NRAS and BRAF mutation frequency in primary oral mucosal melanoma | Q84548771 | ||
| Prognosis of acral melanoma: a series of 281 patients | Q87066412 | ||
| Main roads to melanoma | Q21245465 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study | Q33682137 | ||
| Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells | Q33725172 | ||
| Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. | Q34010098 | ||
| Subungual melanoma. A review of 93 cases with identification of prognostic variables | Q34032958 | ||
| Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. | Q34976858 | ||
| Human melanocyte senescence and melanoma susceptibility genes | Q35146545 | ||
| Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma | Q35782064 | ||
| Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis | Q36757554 | ||
| Acral lentiginous melanoma of the foot and ankle: A case series and review of the literature | Q36909771 | ||
| Melanoma survival in the United States, 1992 to 2005. | Q36961188 | ||
| The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics | Q37290440 | ||
| Acral lentiginous melanoma | Q37872866 | ||
| Acral melanoma: a review of 185 patients with identification of prognostic variables | Q37965515 | ||
| SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant | Q38337665 | ||
| Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. | Q40507438 | ||
| Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. | Q40529472 | ||
| BRAF point mutations in primary melanoma show different prevalences by subtype. | Q40546868 | ||
| The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. | Q41148559 | ||
| Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin | Q41730326 | ||
| Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. | Q42596171 | ||
| Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia. | Q43244288 | ||
| Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006. | Q43541315 | ||
| Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas | Q43652363 | ||
| Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea | Q43998617 | ||
| Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma | Q44036972 | ||
| Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas | Q44763084 | ||
| The CDKN2A and MAP kinase pathways: molecular roads to primary oral mucosal melanoma | Q44795823 | ||
| Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma | Q44932116 | ||
| Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas | Q46648205 | ||
| Subungual melanoma: a study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting | Q46879067 | ||
| P433 | issue | 12 | |
| P921 | main subject | acral lentiginous melanoma | Q4675038 |
| P304 | page(s) | 892-897 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | American Journal of Dermatopathology | Q15754884 |
| P1476 | title | MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma | |
| P478 | volume | 37 |
Search more.